# Bonum Therapeutics

> Bonum Therapeutics is a Seattle biotechnology company building conditionally active biologics - drugs that switch on only where they are needed and switch off everywhere else. Spun out of Good Therapeutics after Roche's $250M acquisition in 2022, Bonum kept the platform blueprint and its founding team, then raised a $93M Series A to extend the approach. Its patented dual-binding antibody (DBA) technology uses a single domain that binds either an effector cytokine or a marker protein, but only one at a time, creating fully reversible medicines aimed at cancer, autoimmunity, metabolic disease and pain.

- **Founded:** 2022
- **Headquarters:** Seattle, Washington, United States
- **Founders:** John Mulligan (Founder & CEO)
- **Team size:** approx. 28 employees (Seattle)
- **Products:** Dual-Binding Antibody (DBA) Platform, LRRC15-controlled IFN-alpha program, Conditionally active cytokine pipeline
- **Notable:** Spun out of Good Therapeutics, whose lead program Roche acquired for $250M upfront in 2022., Raised a $93M Series A within roughly two months of the Roche acquisition., Granted U.S. Patent No. 12,303,567 in August 2025 covering its dual-binding antibody mechanism, with patents also issued in the UK and Australia.

## Products & services

- **Dual-Binding Antibody (DBA) Platform** — A patented protein-engineering platform in which a single antibody domain can bind either an effector (such as a cytokine) or a marker protein, but only one at a time. This creates fully reversible, conditionally active biologics that switch on in the presence of a disease marker and switch off in its absence.
- **LRRC15-controlled IFN-alpha program** — Bonum's most advanced program: a conditionally active interferon-alpha whose activity is gated by the tumor-associated marker LRRC15, concentrating immune-activating signal in the tumor microenvironment while sparing healthy tissue.
- **Conditionally active cytokine pipeline** — Additional preclinical programs applying the DBA mechanism to cytokines including IL-2, IL-12 and TGF-beta, targeting cancer, autoimmune disease, metabolic disorders and pain.

## Achievements

- Spun out of Good Therapeutics, whose lead program Roche acquired for $250M upfront in 2022.
- Raised a $93M Series A within roughly two months of the Roche acquisition.
- Granted U.S. Patent No. 12,303,567 in August 2025 covering its dual-binding antibody mechanism, with patents also issued in the UK and Australia.
- Advanced a conditionally active, LRRC15-controlled IFN-alpha oncology program toward the clinic.
- Retained its full founding scientific team and expanded its Seattle Eastlake offices and labs in 2024.

## Latest updates

- **2025-08** — USPTO granted U.S. Patent No. 12,303,567 protecting Bonum's dual-binding antibody mechanism for conditionally regulated therapeutics; patents also issued in the UK and Australia.
- **2024-07** — Bonum upgraded its Seattle offices and expanded its team as it advanced its lead conditionally active cancer program.
- **2022-11** — Announced a $93M Series A financing to advance its conditionally active therapeutics platform.
- **2022-08** — Launched as a spinout of Good Therapeutics following Roche's $250M acquisition of Good's lead program.

## Links

- Website: https://bonumtx.com
- LinkedIn: https://www.linkedin.com/company/bonum-therapeutics
- Twitter/X: https://twitter.com/BonumTx

---

Profile page: https://yespress.io/bonum-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-15